HTG Molecular Diagnostics, Inc. Stock
Equities
HTGMQ
US40434H3021
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | +66.67% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
Sales 2021 | 8.91M 12.17M | Sales 2022 | 6.37M 8.7M | Capitalization | 3.67M 5.02M |
---|---|---|---|---|---|
Net income 2021 | -17M -23.24M | Net income 2022 | -21M -28.7M | EV / Sales 2021 | 3.96 x |
Net cash position 2021 | 5.74M 7.84M | Net cash position 2022 | 3.41M 4.66M | EV / Sales 2022 | 0.04 x |
P/E ratio 2021 |
-2.19
x | P/E ratio 2022 |
-0.16
x | Employees | 54 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98% |
1 day | +66.67% | ||
Current month | +66.67% | ||
1 month | +66.67% | ||
3 months | +92.31% | ||
6 months | -85.71% | ||
Current year | +92.31% |
Managers | Title | Age | Since |
---|---|---|---|
John Lubniewski
CEO | Chief Executive Officer | 60 | 11-03-31 |
Shaun McMeans
DFI | Director of Finance/CFO | 62 | 12-01-31 |
Chief Administrative Officer | 45 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 15-10-26 | |
Director/Board Member | 59 | 22-01-26 | |
Ann Hanham
CHM | Chairman | 71 | 16-08-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.0025 | +66.67% | 1,835 |
24-04-25 | 0.0015 | -40.00% | 1,088 |
24-04-22 | 0.0025 | 0.00% | 933 |
24-04-19 | 0.0025 | +66.67% | 1,008 |
Delayed Quote OTC Markets, April 26, 2024 at 03:59 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-7.14% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- HTGMQ Stock